These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 161206)

  • 1. Agents affecting osteolysis in patients with breast cancer.
    Coombes RC; Neville AM; Gazet JC; Ford HT; Nash AG; Baker JW; Powles JT
    Cancer Chemother Pharmacol; 1979; 3(1):41-4. PubMed ID: 161206
    [No Abstract]   [Full Text] [Related]  

  • 2. Human calcitonin and malignant osteolysis.
    Nuti R; Righi G; Turchetti V; Vattimo A; Lazzaretto R; Martini G
    Panminerva Med; 1986; 28(1):5-9. PubMed ID: 3960585
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical use of calcitonin in the treatment of osseous localizations in breast carcinoma and multiple myeloma].
    Di Benedetto G; Corsini G; Puppo F; Zavarise GM
    Clin Ter; 1981 Mar; 96(6):605-13. PubMed ID: 7285526
    [No Abstract]   [Full Text] [Related]  

  • 4. [Synthetic salmon calcitonin in the therapeutic management of osteolytic metastases of breast carcinoma].
    Simone C; Racanelli A
    Clin Ter; 1981 Aug; 98(3):247-67. PubMed ID: 7285537
    [No Abstract]   [Full Text] [Related]  

  • 5. Diphosphonates for osteolytic metastases.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
    Lancet; 1985 May; 1(8438):1155-6. PubMed ID: 2860356
    [No Abstract]   [Full Text] [Related]  

  • 6. Human breast tumour-induced osteolysis and prostaglandins.
    Dowsett M; Easty GC; Powles TJ; Easty DM; Neville AM
    Prostaglandins; 1976 Mar; 11(3):447-60. PubMed ID: 948618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional radiograms for assessment of salm-calcitonin therapy for bone metastases from breast carcinoma.
    Geyer J; Quadt C; Perlick E; Starke K; Stier G; Tanneberger S
    Eur J Radiol; 1991; 12(2):124-6. PubMed ID: 2036999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
    Delmas PD; Charhon SA; Chapuy MC; Meunier PJ
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):663-6. PubMed ID: 6523018
    [No Abstract]   [Full Text] [Related]  

  • 10. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
    Andriani A; Beni A; Beni RA; Calistri A; Gelli GF
    Clin Ter; 1981 Jan; 96(2):183-91. PubMed ID: 7237953
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of calcitonin in neoplastic osteolysis].
    Pastorino G; Bianucci M
    Minerva Med; 1983 Mar; 74(13):707-14. PubMed ID: 6835560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metastases from breast cancer treated with calcitonin. Case report.
    Favini G; Arosio A; Libretti A
    Tumori; 1979 Dec; 65(6):713-7. PubMed ID: 543014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma: optimal use of salmon calcitonin in the management of myeloma osteoclastic bone disease.
    Bataille R; Tenoudji-Cohen M; Rossi JF
    Br J Haematol; 1983 Jan; 53(1):170-1. PubMed ID: 6848121
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcitonin or diphosphonates for osteolytic Paget's disease?
    Nagant de Deuxchaisnes C; Rombouts-Lindemans C; Huaux JP; Devogelaer JP; Malghem J; Maldague B
    Lancet; 1980 Feb; 1(8164):374. PubMed ID: 6101833
    [No Abstract]   [Full Text] [Related]  

  • 15. [Results of thyrocalcitonin mithramycin, and indomethacin treatment of a case of hypercalcemia in tumor of the lung].
    Pesce L; Del Torre L; Busolin G; Macaluso S
    Arch Monaldi; 1977; 31(2):119-31. PubMed ID: 141246
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal function and alterations in plasma electrolyte levels in normocalcaemic and hypercalaemic patients with malignant diseases, given an intravenous infusion of mithramycin.
    Fillastre JP; Maitrot J; Canonne MA; Gray H; Jeanne C; Bastit P; Bourgeois T
    Chemotherapy; 1974; 20(5):280-95. PubMed ID: 4278249
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
    Warrell RP
    J Clin Oncol; 1986 Aug; 4(8):1160-1. PubMed ID: 3016204
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone destruction and hypercalcemia in plasma cell myeloma.
    Mundy GR; Bertolini DR
    Semin Oncol; 1986 Sep; 13(3):291-9. PubMed ID: 2945254
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experience with human calcitonin].
    De Bastiani G; Nogarin L; Lazzaretto R
    Minerva Med; 1981 Jun; 72(26):1719-23. PubMed ID: 6166901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.